Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy.
Adv Ther. 2024 Oct;41(10):3778-3791. doi: 10.1007/s12325-024-02968-w. Epub 2024 Aug 28.
Several studies have described increased risk ratios of certain types of malignancies in patients with severe psoriasis. Among these, the lymphoproliferative disorders, including non-Hodgkin's lymphoma, cutaneous T-cell lymphoma and non-melanoma skin cancer, have been described most frequently. In addition to traditional cancer risk factors, some psoriasis treatments may also be implicated as potential carcinogens. The aim of this study was to perform a review of current literature on the association between psoriasis, the therapies against this disease and skin cancer, focusing on both epidemiology and the potential mechanism involved. Some psoriasis treatments, such as psoralen and ultraviolet A (PUVA) therapy and cyclosporine, have been associated with increased risk of skin cancer. Variable data have been reported for anti-tumour necrosis factor (TNF) drugs, whereas other class of biologics, like anti-IL17 and IL23, as well as ustekinumab, seem not to be related to skin cancer risk, such as the case of currently available small molecules.
多项研究描述了重症银屑病患者罹患某些特定类型恶性肿瘤的风险比增加。其中，最常描述的是淋巴增生性疾病，包括非霍奇金淋巴瘤、皮肤 T 细胞淋巴瘤和非黑色素瘤皮肤癌。除了传统的癌症危险因素外，一些银屑病治疗方法也可能被认为是潜在的致癌因素。本研究旨在对当前关于银屑病、针对这种疾病的治疗方法和皮肤癌之间关联的文献进行综述，重点关注流行病学和潜在的相关机制。一些银屑病治疗方法，如补骨脂素和紫外线 A（PUVA）疗法和环孢素，已被认为与皮肤癌风险增加有关。抗肿瘤坏死因子（TNF）药物的报告数据存在差异，而其他类别的生物制剂，如抗 IL17 和 IL23 以及乌司奴单抗，似乎与皮肤癌风险无关，目前可用的小分子药物就是这种情况。
